Skip to main content

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

Annals of Hematology volume 98, pages 1031–1032 (2019)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Berentsen S, Tjønnfjord GE (2012) Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 26:107–115. https://doi.org/10.1016/j.blre.2012.01.002

    Article  CAS  PubMed  Google Scholar 

  2. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 91:460–466

    PubMed  Google Scholar 

  3. Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE (2017) Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 130:537–541. https://doi.org/10.1182/blood-2017-04-778175

    Article  CAS  PubMed  Google Scholar 

  4. Wong EK, Kavanagh D (2015) Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 165:306–320. https://doi.org/10.1016/j.trsl.2014.10.010

    Article  CAS  PubMed  Google Scholar 

  5. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE et al (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552–559. https://doi.org/10.1056/NEJMoa031688

    Article  CAS  PubMed  Google Scholar 

  6. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243. https://doi.org/10.1056/NEJMoa061648

    Article  CAS  PubMed  Google Scholar 

  7. Shapiro R, Chin-Yee I, Lam S (2015) Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. Clin Case Rep 3:942–944. https://doi.org/10.1002/ccr3.399

    Article  PubMed  PubMed Central  Google Scholar 

  8. Roth A, Hüttmann A, Rother RP, Dührsen U, Philipp T (2009) Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 113:3885–3886. https://doi.org/10.1182/blood-2009-01-196329

    Article  PubMed  Google Scholar 

  9. Gupta N, Wang ES (2014) Long-term response of refractory primary cold aggulutinin disease to eculizumab therapy. Ann Hematol 93:343–344. https://doi.org/10.1007/s00277-013-1800-7

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Kenichi Makishima, Naoshi Obara, Kantaro Ishitsuka, Shinichiro Sukegawa, Sakurako Suma, Yusuke Kiyoki, Naoko Baba, Tatsuhiro Sakamoto, Takayasu Kato, Manabu Kusakabe, Hidekazu Nishikii, Naoki Kurita, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Yuichi Hasegawa & Shigeru Chiba

Authors
  1. Kenichi Makishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoshi Obara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kantaro Ishitsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinichiro Sukegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sakurako Suma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yusuke Kiyoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoko Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tatsuhiro Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takayasu Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Manabu Kusakabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hidekazu Nishikii
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naoki Kurita
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yasuhisa Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mamiko Sakata-Yanagimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yuichi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shigeru Chiba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoshi Obara.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Written informed consent was obtained from the patient.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Makishima, K., Obara, N., Ishitsuka, K. et al. High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. Ann Hematol 98, 1031–1032 (2019). https://doi.org/10.1007/s00277-018-3521-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3521-4